RESUMO
Childhood cancer survivors are at increased risk for treatment-related late effects; data are lacking on how coronavirus disease 2019 (COVID-19) infection impacts this cohort. We assessed COVID-19-related symptoms, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) IgG seroprevalence, and rate of COVID-19-related hospitalization among 321 asymptomatic survivors of childhood cancer or transplantation seen for routine long-term follow-up between May and September 2020 in a New York City tertiary cancer center. While 10.9% (n = 35) reported possible COVID-19-related symptoms, 7.8% (n = 20) of those tested had positive SARS-CoV-2 IgG, and one patient (0.3%) required COVID-19-related hospitalization. This report suggests that childhood cancer survivors appear to be at relatively low risk for COVID-19 complications.
Assuntos
Anticorpos Antivirais/sangue , COVID-19/epidemiologia , Sobreviventes de Câncer/estatística & dados numéricos , Neoplasias Hematológicas/terapia , Adolescente , Criança , Pré-Escolar , Feminino , Transplante de Células-Tronco Hematopoéticas/estatística & dados numéricos , Humanos , Imunoglobulina G/sangue , Lactente , Masculino , Cidade de Nova Iorque/epidemiologia , Estudos Retrospectivos , Risco , SARS-CoV-2/imunologia , SARS-CoV-2/isolamento & purificaçãoRESUMO
BACKGROUND: Oral contraceptives (OC) are the most popular contraception in Denmark. Overall figures on use are well described, but more detailed use patterns according to type and age need to be updated. OBJECTIVES: To assess trends in the use of OC including progestogen-only pills among Danish women in 1998-2010 and to describe in detail use patterns in 2010. Design. Annual cross-sectional prescription statistics. SETTING: Denmark. POPULATION: Danish women 10-49 years old. MATERIAL AND METHODS: Analysis of prescription data from the National Registry of Medicinal Products Statistics from 1 January 1998 through 31 December 2010. RESULTS: Combined OC (COC) with 50 µg estrogen decreased their market share from 3% in 1998 to zero in 2010, and COC with 30-40 µg estrogen decreased to 50% in 2010, in contrast, COC with 20 µg estrogen increased to 46% in 2010. Progestogen-only pills accounted for 4%. COC with levonorgestrel decreased, while the use of pills with desogestrel and gestodene among two-thirds of current users was constant. CONCLUSION: Low-dose COCs gradually replaced middle-dose pills. Pills with newer progestogens are used primarily by young women, and 85% of users in 2010 were on products with desogestrel, gestodene, drospirenone or cyproteroneacetate. We still need low-dose pills with 1(st) and 2(nd) generation progestogens on the Scandinavian market.
